GLAXF - GlaxoSmithKline plc
| Previous close | 17.00 |
| Open | 17.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 17.00 - 17.26 |
| 52-week range | 13.48 - 22.74 |
| Volume | |
| Avg. volume | 2,388 |
| Market cap | 70.68B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 12.79 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.70 (4.12%) |
| Ex-dividend date | 18 May 2023 |
| 1y target est | N/A |
- Business Wire
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
PHILADELPHIA, June 01, 2023--GSK announces the COiMMUNITY Initiative to help achieve higher adult vaccination rates in the US
- Business Wire
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
MONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl
- Business Wire
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
PHILADELPHIA, May 03, 2023--US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
- Business Wire
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
LONDON, April 18, 2023--GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion). The acquisition provides GSK access to camlipixant
- Business Wire
GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
PHILADELPHIA, March 14, 2023--GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
- Business Wire
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
PHILADELPHIA, December 11, 2022--GSK plc (LSE/NYSE:GSK) today announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR) in myelofibrosis patients previously treated with an approved Janus kinase (JAK) inhibitor. Additionally, new analyses from MOMENTUM showed
- Business Wire
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
LONDON, July 27, 2022--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.i The approval extends the current indication in the US to include both lupus and ac
- Business Wire
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
PHILADELPHIA, July 11, 2022--GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
- Business Wire
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
PHILADELPHIA, June 29, 2022--GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
- Business Wire
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
PHILADELPHIA, June 06, 2022--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.
